Dove Men+Care Encourages Canadian Dads to Celebrate ‘My Most Important Role' on LinkedIn
As part of the campaign, Canadian Dads are encouraged to use LinkedIn's 'Add position' feature to reflect their role as a father and join a growing movement of men reshaping the traditional definition of masculinity, identity, and care. Making fatherhood LinkedIn-official, Dove Men+Care sparks a broader conversation that urges men to treat personal milestones with the same importance and visibility as professional ones.
'Too often, men proudly share promotions, but rarely the presence and care they bring at home,' said Divya Singh, General Manager, Personal Care, Unilever Canada. 'With this campaign, we are redefining success to include care and celebrate the powerful role fathers and father figures play beyond the workplace.'
To kickstart the movement, Dove Men+Care partnered with Founder/CEO Ross Simmonds, Sports Commentator Donnovan Bennett, Celebrity Chef and TV host Dave Rocco, Innovation Strategist Shawn Kanungo. Each thought leader, known in Canada for their professional achievements, are sharing their personal fatherhood stories alongside custom visuals designed by Toronto-based illustrator Mateusz Napieralski. Canadians are encouraged to download and re-share these custom illustrations along with their own fatherhood update and journey.
"When men see fatherhood as a vital part of who they are, it positively shapes their mental health and emotional well-being," said Dr. Andrew Howlett, a Toronto-based Child and Family Psychiatrist, and co-founder of the Fathers' Mental Health Network. "By valuing and supporting active fatherhood, we help dads feel recognized and empowered - building resilient families and healthier communities."
As a long-time partner of Dove Men+Care, Dad Central, a national organization that provides research, programming, resources, and a community to support father involvement, is helping amplify the campaign through its extensive community network. The group is also contributing expert insight on the cultural importance of active fatherhood and its long-term impact on society.
The campaign runs nationally in the lead-up to Father's Day, encouraging Dads across Canada to take part on LinkedIn. To learn more about Dove Men+Care, visit dove.com/men-care. To find out more about Dad Central visit: https://dadcentral.ca.
About Dove Men+Care
Dove Men+Care is the first range of products from Dove developed specially for men. Manufactured by Unilever, the line includes the #1 dermatologist recommended male bar and body wash brand. Launched in 2010, the Dove Men+Care portfolio includes bars, body washes, anti-perspirant/deodorants, and hair care. Dove Men+Care is available nationwide in food, drug, and mass outlet stores.
About Unilever
Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024.
For more information about Unilever and our brands, please visit www.unilever.com.
About Unilever in North America
Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024.
Our leading brands in North America include Dove, Hellmann's, Vaseline, Degree, Axe, TRESemmé, Knorr, Magnum, Ben & Jerry's, Nutrafol, Liquid I.V., Paula's Choice, and Dermalogica.
For more information on Unilever U.S. and its brands visit: www.unileverusa.com
For more information on Unilever Canada and its brands visit: www.unilever.ca
About Unilever in Canada
Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024.
Our leading brands in Canada include Dove, Vaseline, Degree, Axe, SheaMoisture, TRESemmé, Knorr, Hellmann's, Breyers, Magnum, Ben & Jerry's, Liquid I.V., and OLLY.
For more information on Unilever Canada and visit: www.unilever.ca or www.unilever.ca/fr.
About Dad Central
Dad Central is a national non-profit organization dedicated to supporting and promoting responsible father involvement in Canada. Through evidence-based research, resources, and community programming, Dad Central helps fathers, families, and organizations recognize and strengthen the important role dads play in child development and family well-being. With over two decades of experience, Dad Central works to ensure every child has the opportunity to benefit from an involved and caring father.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
44 minutes ago
- Medscape
Cognitive Therapy Offers Sustained Relief of Low Back Pain
A personalized protocol involving self-managed cognitive functional therapy (CFT) was associated with sustained symptom improvement at 3 years in patients with chronic low back pain in a phase 3 follow-up study. The three-armed RESTORE trial assessed adult patients in Australia with chronic disabling low back pain, showing effectiveness for CFT with or without motion sensor biofeedback compared with usual care for up to 1 year. In this new extension analysis of RESTORE, both CFT treatments were still more effective than usual care at 3 years, with greater reductions in both pain intensity and activity limitation. Interestingly, no differences in outcomes were found between the CFT-only group and the CFT plus biofeedback group. 'It shows that if we empower patients with knowledge and skills to manage back pain, including future flare-ups that are almost inevitable, then we can markedly reduce the massive personal and societal burden of back pain,' lead author Mark Hancock, PhD, Spinal Pain Research Center, Macquarie University, Sydney, Australia, told Medscape Medical News. 'We hoped to see these results, given the intervention design, but we were still somewhat surprised how well the effects lasted over time,' he added. The findings were published online on August 5 in The Lancet Rheumatology . Building on 'Unusual' Initial Findings Hancock noted that most treatments for low back pain produce small, short-lasting benefits. 'The CFT intervention is specifically designed to have long-term effects, as it gives people the skills, knowledge, and confidence to self-manage. The results we previously published showed the effects were sustained at 1 year, which is unusual, and we wanted to see if it remained effective at 3 years,' he said. In the original RESTORE trial, the investigators recruited adult patients who had low back pain lasting more than 3 months and randomly assigned them to receive one of three treatments: CFT only (n = 164), CFT plus biofeedback (n = 163), or usual care (n = 165). The CFT groups received up to seven treatments over 12 weeks plus a booster session at 26 weeks, all of which were delivered by trained physiotherapists. Investigators noted that CFT targets biopsychosocial barriers to recovery and has three components that are based on an individual patient's goals. These components include 'making sense of pain,' exposure with control, and lifestyle change. Both CFT groups wore movement sensors during their sessions, but only the CFT plus biofeedback group and their physiotherapists had access to the data. Usual care involved treatment that was chosen by the patient themselves and/or recommended by their healthcare provider. The new 3-year follow-up included 312 of the original participants (mean age, 48 years; 60% women) and between 60% and 65% of each of the original treatment groups. The extension's primary outcome was self-reported pain-related physical activity limitation, as measured on the Roland-Morris Disability Questionnaire. The secondary outcome was pain intensity, as measured by the numeric pain rating scale. Long-Term Pain Reduction Results showed that CFT with biofeedback was more effective in reducing activity limitation at the 3-year mark vs usual care (mean difference, -4.1; P < .0001), as was CFT alone (mean difference, -3.5; P < .0001). Additionally, CFT with or without biofeedback was more effective in reducing pain intensity vs usual care (mean differences, -1.5 and -1.0, respectively; P < .0001 for both). For both measures, the differences between the two CFT groups were not significant. Sensitivity analyses showed similar, although slightly smaller, effects. In addition, 49% of the CFT plus biofeedback and 43% of the CFT-only groups maintained recovery level scores between the 1-year and 3-year follow-ups compared with 17% of the usual care group. 'These long-term effects are novel and provide the opportunity to markedly reduce the effect of chronic back pain if the intervention can be widely implemented,' the investigators wrote. They noted that this would include an increase in clinician training and replication studies in other populations. 'This type of biopsychosocial intervention is widely recommended in guidelines, but the evidence [for it] is now becoming much stronger,' Hancock said. 'Many clinicians aim to deliver these interventions, but they often find it hard, especially if they were trained in a more pure biomedical way of thinking. There are now more resources to assist clinicians in upskilling in these approaches,' he added. 'Cautious Optimism' In an accompanying editorial, Dimitrios Lytras, PhD, Department of Physiotherapy, International Hellenic University, Thessaloniki, Greece, applauded how the study was conducted. 'Methodologically, RESTORE is exemplary: a pragmatic, multicenter trial embedded in routine care [and] supported by thorough therapist training,' Lytras wrote. He added that the results 'offer cautious optimism' and a shift from passive care models to ones that are more patient-centered. The addition of biofeedback not leading to added benefit could be explained by the fact that CFT 'already incorporates rich feedback mechanisms, making supplementary sensor input redundant,' he noted. Lytras wrote that the intervention is also low risk and high value. Durable Functional Gains Commenting for Medscape Medical News, Sean Mackey, MD, PhD, Redlich professor and chief of the Division of Pain Medicine at Stanford Medicine, Palo Alto, California, said the study showed durable functional gains and modest pain changes. The dose of seven visits over 12 weeks plus a 26-week booster was 'lean,' but the effects held, which was 'pleasantly surprising,' said Mackey, who was not involved with the research. However, he did note a few caveats, including that only 63% of the randomized cohort contributed to the 3-year data. In addition, 'those followed were less severe at baseline and did better at 1 year, though loss to follow-up was nondifferential by arm,' he said. In reflecting on the study design, Mackey noted that an 'attention-matched active comparator to blunt performance and expectancy bias' would have been helpful. He pointed out that the researchers themselves acknowledged that usual care was not contact-matched. He added that it would also have been valuable to include data on 3-year adverse events, healthcare utilization, and costs. If future research confirms its generalizability to other countries, Mackey said he would recommend clinicians 'adopt the CFT package' of graded exposure with a control and lifestyle coaching, schedule 6-8 visits plus a 6-month booster, measure function as the primary outcome, and set expectations for about a one-point reduction in pain. He recommended against adding sensor biofeedback because 'it didn't help.'
Yahoo
9 hours ago
- Yahoo
Northwest Healthcare Properties Real Estate Investment Trust Reports Second Quarter 2025 Results, Suspends Its Distribution Reinvestment Plan, and Appoints Zachary Vaughan to the Board of Trustees
Toronto, Ontario--(Newsfile Corp. - August 12, 2025) - Northwest Healthcare Properties Real Estate Investment Trust (TSX: (the "REIT" or "Northwest"), a global investor and operator of healthcare infrastructure assets in North America, Australasia, Brazil, and Europe, announces results for the three and six months ended June 30, 2025. In addition, the REIT announces the suspension of its distribution reinvestment plan (the "DRIP") and the appointment of Zachary Vaughan to the Board of Trustees (the "Board"). Zachary Vaughan, CEO of Northwest, commented, "Having just joined Northwest in July, I am excited by the caliber of the portfolio and the strength of the team. The assets we own and operate are critical components of healthcare infrastructure. Our assets have long-term demand drivers, recession-resistant cash flows and very low obsolescence risk. Our cash flows are backed by outstanding underlying credit, often government supported, with long-term indexation. Given Northwest's unique position as a leader in healthcare infrastructure, we are well positioned for future growth. "Our Q2 2025 results reflect continued operational momentum, with improvements in AFFO per unit, a lower payout ratio, and continued execution of our capital recycling strategy with over $282 million in non-core asset sales completed year to date. "Looking ahead, we're focused on disciplined capital allocation and unlocking value through strategic asset management and selective dispositions. This will provide us with flexibility to further reduce debt, reinvest in our core portfolio, and pursue accretive growth opportunities that drive long-term value for unitholders." Q2 2025 Highlights Highlights for Q2 2025 and events subsequent to the quarter are set out below: Revenue from investment properties was $99.0 million for Q2 2025, a decrease of 16.9% from Q2 2024 driven by the disposition of non-core assets during 2024 and 2025 to date, partially offset by solid same property revenue growth; Same Property Net Operating Income ("SPNOI") increased by 2.8% to $73.2 million for Q2 2025, over Q2 2024, reflecting steady growth across all regions (see Exhibit 1); General and administrative expenses, excluding unit-based compensation and employee termination benefits and associated costs, were $12.6 million for Q2 2025, a decrease of $0.5 million from Q2 2024, primarily due to headcount reduction and simplification of the REIT's business; Net income for Q2 2025 was $32.6 million compared to net loss of $127.2 million in Q2 2024, primarily due to a decrease in mortgage and loan interest expense, positive fair value adjustment on investment properties, and unrealized foreign exchange gains, partially offset by fair value loss on revaluation of financial instruments and by lower net operating income as a result of disposition activity; Adjusted funds from operations ("AFFO") was $0.10 per unit in Q2 2025 compared to $0.10 per unit in Q1 2025 and $0.09 per unit in Q2 2024, resulting in an AFFO payout ratio of 88% in Q2 2025 compared to 92% in Q1 2025 and 105% in Q2 2024 (see Exhibit 2); During Q2 2025, the REIT recorded fair value gains on investment properties of $13.6 million, compared to fair value losses of $172.4 million in Q2 2024. The fair value movements were mainly attributable to changes in valuation parameters, incorporating market evidence when available and rent reviews. The REIT's portfolio cap rate as at June 30, 2025 is 6.3%; The REIT's leverage was 48.5% at the end of Q2 2025, as compared to 50.0% as at December 31, 2024, driven by proactive debt repayment from dispositions; and Strong operating performance in Q2 2025 was supported by a stable, long-term lease maturity profile with a weighted-average lease expiry ("WALE") of 13.5 years and a global portfolio occupancy rate of 97%. Operations and Leasing The REIT's consolidated SPNOI increased by 2.8% in Q2 2025 compared to the prior year period, driven mainly by inflationary rent adjustments, rentalised capital spend, and improved recoveries reflecting steady growth in the REIT's underlying lease income. Regionally, SPNOI increased by 2.0% in North America, 4.6% in Brazil, 2.3% in Europe, and 2.6% in Australasia (see Exhibit 1). In Q2 2025, the REIT completed 298,000 square feet of new, renewal and early leasing, achieving a strong renewal rate of 89%. As previously disclosed, in March 2025, following sector margin pressures exacerbated by its capital structure, Healthscope Pty Ltd ("HSO"), the REIT's second largest tenant, occupying 12 properties and accounting for 6.1% of the REIT's proportionate revenues, requested temporary relief from its lender syndicate and landlords, including Northwest. In May 2025, HSO's parent entities entered receivership, with its lenders appointing McGrathNicol Restructuring to work with HSO management to complete an orderly sale of the business. All hospitals continue to operate as usual, and the company has received an additional A$100m facility to support operations. In July 2025, (i) the HSO receiver repaid 50% of the previously announced rent deferral accrued to June 30, 2025, and (ii) Northwest agreed to an updated rent deferral arrangement with the HSO receiver starting July 1st whereby 10% of ongoing rent will be deferred. All deferrals are expected to be repaid by March 31, 2026 or upon completion of sale of material assets. The deferred rent has priority over senior debt. The receiver-led sale process commenced in late July, and it is anticipated that a new owner will be confirmed in Q4 2025, with the transition process and timing of regulatory approvals to be determined. Northwest maintains constructive dialogue with the receiver and ongoing discussions with prospective operators participating in the process. As of today, all rent owing to the REIT from HSO (other than the rent subject to rent deferral arrangements) has been paid and HSO continues to meet all lease obligations. Disposition Activity and Assets Held for Sale The REIT's capital recycling during the quarter, including subsequent events, has generated over $231 million of proceeds as detailed below. During Q2 2025, the REIT sold its shares in Assura through two on-market transactions for total proceeds of $209.3 million (£114.7 million) resulting in a full divestment of the shares. The REIT's investment in Assura was acquired as partial consideration for the REIT's disposition of its UK portfolio in August 2024 at a value of $177 million (£100 million), resulting in a gain on disposition of approximately $32.3 million (£14.6 million). Proceeds were used to repay related debt and corporate facilities. In Q2 2025, the REIT completed the sale of one income producing property in North America, one development property in Europe, and one development property in Australasia, classified as assets held for sale at their fair value of $22.1 million. The proceeds were used to repay directly attributable debt and outstanding balances on credit facilities. As at June 30, 2025, the REIT held one income producing property with a value of $34.3 million as classified as held for sale. Financing Activity During the quarter, the REIT also extended or refinanced several debt facilities including Canadian mortgages and Australasian term loans. On July 29, 2025, the REIT amended the terms of its revolving credit facility. The amendment extends the maturity date of the facility to July 2027 and moves the REIT to grid pricing based on its credit rating, reducing the REIT's cost of borrowing by 65 basis points. The amendment also provides a $100 million accordion commitment, subject to incremental security and lender approval, that provides the REIT flexibility with mortgage maturities as it transitions away from amortizing debt. Subsequent to quarter end, the REIT repaid Canadian mortgages totaling $40.8 million, with a weighted average interest rate of 2.67%, using capacity on its revolving credit facility. As of today, the REIT has $20.9 million of Canadian mortgages with 2025 maturities that will be repaid with capacity from the revolving credit facility and $11.7 million of European mortgages that will be renewed in the ordinary course. Of the REIT's proportionate 2026 debt maturities totaling $424 million, over 50% or approximately $226 million are maturing in the fourth quarter of 2026, with the remainder relating to mortgages. The REIT currently has approximately $230 million of available liquidity, consisting of cash and the unused portion of its credit facilities. Selected Operating and Financial Information: (unaudited) June 30, 2025 December 31, 2024 as at Assets Under Management $ 8,220,857 $ 8,281,609 Number of properties 168 172 Gross leasable area (sf) 15,750,688 15,886,309 Occupancy 96.6 % 96.4 % Weighted Average Lease Expiry (Years) 13.5 13.6 Debt $ 2,890,915 $ 3,027,154 Debt to Gross Book Value 48.5 % 50.0 % Weighted average capitalization rate 6.3 % 6.2 % Economic Weighted Average Interest Rate 4.8 % 5.5 % (unaudited) Three months ended June 30, Six months ended June 30, ($000's, except per unit amounts) 2025 2024 2025 2024 Net Operating Income $ 76,308 $ 93,976 $ 153,456 $ 189,428 Net Income (Loss) attributable to unitholders $ 32,621 $ (127,224 ) $ 17,091 $ (165,841 ) Funds from Operations ("FFO") excluding accelerated amortization of deferred financing charges (1), (2), (3) $ 27,968 $ 22,314 $ 50,740 $ 49,271 Adjusted Funds from Operations ("AFFO") (1) $ 25,407 $ 21,186 $ 49,755 $ 48,865 FFO, excluding accelerated amortization of deferred financing charges, per unit - diluted (1), (2), (3) $ 0.11 $ 0.09 $ 0.22 $ 0.20 AFFO per unit - diluted (1), (2) $ 0.10 $ 0.09 $ 0.20 $ 0.20 Distributions per unit $ 0.09 $ 0.09 $ 0.18 $ 0.18 AFFO Payout Ratio - diluted 89 % 105 % 90 % 90 % (1) FFO and AFFO are not measures recognized under IFRS and do not have standardized meanings prescribed by IFRS. See Performance Measurement in the REIT's MD&A. The adjustments to determine FFO and AFFO have been presented on a proportionate basis. See "Non-IFRS Financial Measures", Exhibit 1 and Exhibit 2. (2) Included in FFO and AFFO for the six months ended June 30, 2024, is $6.7 million related to interest rate cap derivative arrangements, which matured during the three months ended March 31, 2024, the impact of which is $0.03 per unit. (3) For the three and six months ended June 30, 2025, FFO and FFO per unit excludes $1.4 million and $3.4 million of accelerated amortization of deferred financing charges due to the early repayment of debt using proceeds from the sale of Assura units during the quarter and the issuance of the $500 million senior unsecured debentures in February 2025. FFO and FFO per unit including accelerated amortization of deferred financing charges is $28.0 million or $0.11 per unit and $54.1 million or $0.22 per unit, respectively. DRIP Suspension The REIT also announces today that it has suspended its DRIP until further notice. The REIT's unit price continues to trade at a meaningful discount to net asset value ("NAV") per unit, and the issuance of units under the DRIP runs counter to the REIT's focus of optimizing capital structure and driving superior growth in NAV per unit and returns over time. Commencing with the September 2025 distribution (payable on or about October 15, 2025), unitholders enrolled in the DRIP will receive distribution payments in cash. If the REIT elects to reinstate the DRIP in the future, unitholders that were enrolled in the DRIP at the time of its suspension and remain enrolled at the time of its reinstatement will automatically resume participation in the DRIP. Appointment of Zachary Vaughan to the Board of Trustees The REIT is pleased to announce the appointment of Mr. Zachary Vaughan, the REIT's current CEO, to the Board effective today, August 12, 2025, as a non-independent trustee. Mr. Vaughan's strong real estate experience will be valuable to the Board. Mr. Vaughan's appointment will fill the vacancy left following the retirement of Mr. Dale Klein on May 27, 2025 at the REIT's 2025 annual general meeting. Corporate Presentation Download the Company's Updated Corporate Presentation: Q2 2025 Results Conference Call The REIT will be hosting its Q2 2025 conference call on Wednesday, August 13, 2025 at 10:00 a.m. ET. The dial-in numbers for the conference call are as follows: North America (toll free): 1-833-752-3625 Overseas or local (Toronto): 1-647-846-8435 Link to audio webcast: A replay will be available until August 20, 2025, by accessing: US/Canada (toll free): 1-855-669-9658 International: 1-412-317-0088 Replay Access Code: 7483273 About Northwest Northwest provides investors with access to a portfolio of high-quality international healthcare real estate infrastructure comprised as at August 12, 2025, of interests in a diversified portfolio of 168 income-producing properties and 15.8 million square feet of gross leasable area located throughout major markets in North America, Australasia, Brazil and Europe. The REIT's portfolio of medical outpatient buildings, clinics, and hospitals is characterized by long-term indexed leases and stable occupancies. Northwest leverages its global workforce in eight countries to serve as a long-term real estate partner to leading healthcare operators. For additional information please visit: Contacts Zach Vaughan, CEO, Stephanie Karamarkovic, CFO, Alyssa Barry, Investor Relations, investors@ (416) 366-2000 Ext. 2202 Non-IFRS Measures Some financial measures used in this press release, such as SPNOI, FFO, FFO per Unit, AFFO, AFFO per Unit, AFFO Payout Ratio, NAV, NAV per unit, and Proportionate Investment Properties are used by the real estate industry to measure and compare the operating performance of real estate companies, but they do not have any standardized meaning prescribed by IFRS. These non-IFRS financial measures and non-IFRS ratios should not be construed as alternatives to financial measures calculated in accordance with IFRS. The REIT's method of calculating these measures and ratios may differ from the methods of other real estate investment trusts or other issuers, and accordingly may not be comparable. Further, the REIT's definitions of FFO and AFFO differ from the definitions recommended by REALPAC. These non-IFRS measures are more fully defined and discussed in the exhibits to this news release and in the REIT's Management's Discussion and Analysis ("MD&A") for the three and six months ended June 30, 2025, in the "Performance Measurement" and "Results from Operations" sections. The MD&A is available on SEDAR+ at Forward-Looking Statements This press release may contain forward-looking statements with respect to the REIT, its operations, strategy, financial performance and condition. These statements generally can be identified by words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe", "normalized", "contracted", or "continue" or the negative thereof or similar variations. Forward-looking statements in this press release may include statements concerning HSO's rent deferral arrangements. the ongoing operation of HSO's hospitals, the impact of its sustainability efforts, future debt repayment and renewal, and the REIT being well positioned for growth, to deliver on its objectives and create long term value for unitholders. The REIT's actual results and performance discussed herein could differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on numerous assumptions which may prove incorrect, and which could cause actual results or events to differ materially from the forward-looking statements. Such assumptions include, but are not limited to (i) assumptions relating to the continued operation of HSO's hospitals and HSO's ability and willingness to pay its deferred rent in accordance with its agreements; (ii) the REIT's properties continuing to perform as they have recently, (iii) various general economic and market factors, including exchange rates remaining constant, local real estate conditions remaining strong, and interest rates remaining at current levels or decreasing, (iv) the availability of equity and debt financing to the REIT and the REIT's ability to refinance, or extend the maturity of, its existing debt, (v) the REIT's commitment to sustainability objectives and the impact thereof, (vi) savings resulting from the REIT's workforce reduction initiatives not being reallocated to other matters, and (vii) the impact that suspending the DRIP will have on the REIT's focus of optimizing capital structure and driving growth in NAV per unit and returns over time. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including that the transactions contemplated herein are completed. Important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulations, and the factors described under "Risks and Uncertainties" in the REIT's Annual Information Form and the risks and uncertainties set out in the MD&A which are available on SEDAR+ at These cautionary statements qualify all forward-looking statements attributable to the REIT and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and, except as expressly required by applicable law, the REIT assumes no obligation to update such statements. NORTHWEST HEALTHCARE PROPERTIES REAL ESTATE INVESTMENT TRUST Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss) (in thousands of Canadian dollars) Unaudited Three months ended June 30, Six months ended June 30,2025 2024 2025 2024 Net Property Operating Income Revenue from investment properties $ 99,004 $ 119,141 $ 210,651 $ 252,686 Property operating costs 22,696 25,165 57,195 63,25876,308 93,976 $ 153,456 $ 189,428 Other Income (loss) Interest and other 2,548 3,356 8,729 6,759 Management fees 3,590 3,366 7,363 7,216 Share of profit (loss) of equity accounted investments 4,648 (13,299 ) (4,094 ) (9,984 )10,786 (6,577 ) $ 11,998 $ 3,991 Expenses and other Interest expense 30,775 53,756 65,865 109,189 General and administrative expenses 14,891 13,454 29,739 28,991 Transaction costs 2,390 4,567 11,822 6,934 Foreign exchange (gain) loss (5,474 ) 861 (7,293 ) (12,869 )42,582 72,638 $ 100,133 $ 132,245 Income before finance income (expense), net gain (loss) on financial instruments, net gain (loss) on dispositions, and fair value adjustments 44,512 14,761 $ 65,321 $ 61,174 Finance income (expense) Amortization of financing costs (2,796 ) (4,271 ) (6,145 ) (9,451 ) Class B exchangeable unit distributions - - - 63 Fair value adjustment of Class B exchangeable units - - - (205 ) Accretion of financial liabilities (397 ) (424 ) (3,816 ) (4,432 ) Fair value adjustment of convertible debentures (206 ) 4,283 (10,691 ) (1,692 ) Convertible debenture issuance costs - - - (27 ) Net gain (loss) on financial instruments (8,377 ) 5,737 20,422 11,349 Fair value adjustment of investment properties 13,619 (172,417 ) (32,728 ) (244,120 ) Net loss on disposals of assets (3,379 ) (4,905 ) (4,778 ) (10,097 ) Fair value adjustment of unit-based compensation liabilities 588 806 (882 ) 1,161 Income (loss) before taxes 43,564 (156,430 ) $ 26,703 $ (196,277 ) Current tax expense 3,529 3,628 7,138 6,394 Deferred tax expense (recovery) 7,414 (32,834 ) 2,474 (36,830 ) Income tax expense (recovery) 10,943 (29,206 ) $ 9,612 $ (30,436 ) Net income (loss) $ 32,621 $ (127,224 ) $ 17,091 $ (165,841 ) Net income (loss) attributable to: Unitholders $ 25,960 $ (122,338 ) $ 25,070 $ (169,945 ) Non-controlling interests 6,661 (4,886 ) (7,979 ) 4,104$ 32,621 $ (127,224 ) $ 17,091 $ (165,841 ) Exhibit 1 – Constant Currency Same Property NOI Constant Currency Same Property NOI, sometimes also presented as "Same Property NOI" or "SPNOI", is a non-IFRS financial measure, defined as NOI for investment properties that were owned for a full reporting period in both the current and comparative year, subject to certain adjustments including: (i) straight-line rental revenue recognition; (ii) amortization of operating leases; (iii) lease termination fees; and (iv) non-recurring transactions that are not expected to recur (v) excluding properties held for redevelopment and (vi) excluding impact of foreign currency translation by converting the foreign currency denominated SPNOI from comparative period at current period average exchange rates. SPNOI is more fully defined and discussed in the REIT's MD&A (see "Performance Measurement"). SAME PROPERTY NOIThree months ended June 30, Six months ended June 30,2025 2024 Var % 2025 2024 Var % Same property NOI (1) North America $ 20,505 $ 20,095 2.0% $ 41,135 $ 40,019 2.8% Brazil 13,876 13,271 4.6% 27,849 26,658 4.5% Europe 8,409 8,221 2.3% 16,527 16,176 2.2% Australasia 30,366 29,604 2.6% 61,539 59,144 4.0% Same property NOI (1) $ 73,156 $ 71,191 2.8% $ 147,050 $ 141,997 3.6% Impact of foreign currency translation - 184 - 53 Straight-line rental revenue recognition 59 595 812 1,831 Amortization of operating leases (29 ) (34 ) (59 ) (72 ) Lease termination fees 14 33 14 102 Other transactions (194 ) (42 ) (137 ) 449 Developments 2,767 156 4,498 477 Dispositions 535 21,893 1,278 44,591 NOI $ 76,308 $ 93,976 (18.8)% $ 153,456 $ 189,428 (19.0)% (1) Same property NOI is a non-IFRS measure, defined and discussed in the REIT's MD&A. Exhibit 2 – Funds From Operations and Adjusted Funds from Operations Reconciliation FFO is a supplemental non-IFRS industry wide financial measure of a REIT's operating performance. The REIT calculates FFO based on certain adjustments to net income (loss) (computed in accordance with IFRS) as detailed below. FFO is more fully defined and discussed in the MD&A (see "Performance Measurement" and "Funds From Operations"). For the three and six months ended June 30, 2025, FFO was $26.5 million including accelerated amortization of deferred financing costs as a result of early repayment of the underlying debt, using proceeds from the senior unsecured debentures. Excluding the impact of $1.4 million of accelerated amortization of deferred financing costs, FFO for the three and six months ended June 30, 2025 is $28.0 million or $0.11 per unit. FUNDS FROM OPERATIONS ("FFO") Three months ended June 30, Six months ended June 30, (unaudited) 2025 2024 2025 2024 Net income (loss) attributable to unitholders $ 25,960 $ (122,338 ) $ 25,070 $ (169,945 ) Add / (Deduct): Fair market value losses (gains) (2) (6,995 ) 166,290 6,941 245,345 Finance cost - Exchangeable Unit distributions - - - (63 ) Revaluation of financial liabilities 397 424 3,816 4,432 Unrealized foreign exchange loss (gain) (4,201 ) 752 (5,886 ) (13,291 ) Deferred taxes 3,796 (33,922 ) 1,502 (38,512 ) Transaction costs 2,384 4,568 11,816 7,030 Net loss on disposal of assets 3,199 4,813 4,566 9,831 Convertible Debenture issuance costs - - - 27 Internal leasing costs 439 293 839 651 Property taxes accounted for under IFRIC 21 8 (74 ) 28 61 Net adjustment for lease liabilities 102 (125 ) 21 (250 ) Employee termination benefits and related expenses 1,234 - 1,616 - Other FFO adjustments 198 1,633 411 3,955 FFO (1) (2) $ 26,521 $ 22,314 50,740 49,271 FFO per Unit - Basic (1) (2) $ 0.11 $ 0.09 $ 0.20 $ 0.20 FFO per Unit - Diluted (3) $ 0.11 $ 0.09 $ 0.20 $ 0.20 Weighted average units outstanding Basic 248,856,278 246,032,139 248,482,289 245,706,653 Diluted (3) 249,941,309 247,415,816 249,528,523 247,062,996 (1) FFO and AFFO are not measures recognized under IFRS and do not have standardized meanings prescribed by IFRS. See Performance Measurement in the REIT's MD&A. The adjustments to determine FFO and AFFO have been presented on a proportionate basis. (2) Included in FFO for the six months ended June 30, 2024 is $6.7 million related to premiums paid in connection with interest rate cap derivatives, the impact of which is $0.03 per unit. (3) Diluted units include the impact of vested deferred trust units and the convertible debentures, that would have a dilutive effect upon conversion. AFFO is a supplemental non-IFRS financial measure of a REIT's operating performance and is intended to reflect a stabilized business environment. The REIT calculates AFFO as FFO, plus/minus certain adjustments as detailed below. AFFO is more fully defined and discussed in the MD&A (see "Performance Measurement" and "Adjusted Funds From Operations"). ADJUSTED FUNDS FROM OPERATIONS (unaudited) Three months ended June 30, Six months ended June 30,2025 2024 2025 2024 FFO (1)(2) $ 26,521 $ 22,314 $ 50,740 $ 49,271 Add / (Deduct): Amortization of transactional deferred financing charges 1,447 2,031 3,350 4,816 Unit-based compensation expense 1,018 270 3,591 2,819 Straight-line revenue (543 ) (513 ) (1,849 ) (1,699 ) Leasing costs and non-recoverable maintenance capital expenditures (3,036 ) (2,916 ) (6,077 ) (6,342 ) AFFO (1) $ 25,407 $ 21,186 $ 49,755 $ 48,865 AFFO per Unit - Basic (1)(2) $ 0.10 $ 0.09 $ 0.20 $ 0.20 AFFO per Unit - diluted (2) $ 0.10 $ 0.09 $ 0.20 $ 0.20 Distributions per Unit $ 0.09 $ 0.09 $ 0.18 $ 0.18 Weighted average units outstanding: Basic 248,856,278 246,032,139 248,482,289 245,706,653 Diluted (2) 249,941,309 247,415,816 249,528,523 247,062,996 (1) FFO and AFFO are not measures recognized under IFRS and do not have standardized meanings prescribed by IFRS. See Performance Measurement in the REIT's MD&A. The adjustments to determine FFO and AFFO have been presented on a proportionate basis. (2) Included in FFO for the six months ended June 30, 2024 is $6.7 million related to premiums paid in connection with interest rate cap derivatives, the impact of which is $0.03 per unit. (3) Diluted units include the impact of vested deferred trust units and the convertible debentures, that would have a dilutive effect upon conversion. To view the source version of this press release, please visit Sign in to access your portfolio
Miami Herald
10 hours ago
- Miami Herald
As Miami-Dade faces budget crunch, fight over healthcare heads for a showdown
Managing healthcare bills for Miami-Dade's roughly 31,000 county employees is big business, and that's prompting a big fight at the County Commission. At issue is a proposal by Mayor Daniella Levine Cava to drop the county's longtime healthcare provider, AvMed, for a national competitor, Aetna — something the mayor claims would save the county about $40 million as it faces a major budget crunch. The fight to win the county's healthcare contract has gotten messy enough that commissioners are holding a special meeting Wednesday dedicated solely to picking a winner. AvMed, based in Doral, argues Levine Cava is rushing the effort ahead of a fall open-enrollment period that's bound to be chaotic if a new provider takes over. AvMed also points to high customer-service rankings as a selling point — particularly with management based in the Miami area. But Levine Cava points to a pair of consultant studies showing that Aetna's national purchasing power would bring Miami-Dade cheaper healthcare costs in a year of budget strains. AvMed, based in Doral, and Aetna, a Connecticut-based subsidiary of the CVS drugstore chain, each want to manage the crucial billing process — including reimbursement rates for healthcare providers. Unions representing county employees are divided. The police union backs keeping AvMed, while the transit union wants to switch to Aetna. In a recent Miami Herald op-ed, Levine Cava said Aetna will bring both savings and expanded options for county employees. 'Partnering with Aetna means not only financial savings for the county but better healthcare access and quality for our workforce,' she wrote. AvMed, which has contracts across Florida, rejects the notion that Aetna will be cheaper for Miami-Dade and points to a recent J.D. Power ranking giving it the top scores for customer service in Florida. AvMed first won the county contract in 2016 and is encouraging Miami-Dade to stick with a healthcare company that has proven itself. 'By continuing its partnership with AvMed, Miami-Dade County can ensure uninterrupted access to the #1 ranked health plan in Florida,' the company said in a statement, referencing the J.D. Power ranking. If the county switches providers, Aetna would earn administrative fees from Miami-Dade worth about $15 million a year. AvMed's fees are lower, at $10 million. But the fight comes over the much larger county expense involved in the agreement: what Miami-Dade pays providers for medical care and supplies, including prescriptions. Like most large governments, Miami-Dade uses its own cash to pay medical expenses, rather than relying on an insurance company to reimburse providers. Under the 'self-insured' model, Miami-Dade can save money if reimbursement rates drop for doctors, pharmacies and other providers used by county employees. Miami-Dade's medical expenses currently hover around $600 million a year, according to county estimates. The county's insurance company negotiates the rates behind those expenses, and Aetna claims it can lower Miami-Dade's healthcare costs over the life of the seven-year contract. Two healthcare consultants hired by Miami-Dade back up that contention, estimating yearly savings of around $40 million when calculating how much the county would pay under each competitor's reimbursement rates. Commissioners have devoted a rare special meeting to deciding the contract award, placing board members in the position of refereeing between competing claims in the complicated realm of healthcare finances and reimbursement rates. 'I'm not for Aetna. I'm not for AvMed,' Commissioner Roberto Gonzalez said during a July 16 discussion of the healthcare contract. 'I'm for whatever is best for the employees of Miami-Dade County.'
